4//SEC Filing
Medicxi Growth Co-Invest I LP 4
Accession 0000899243-21-043033
CIK 0001501796other
Filed
Nov 3, 8:00 PM ET
Accepted
Nov 4, 5:00 PM ET
Size
32.1 KB
Accession
0000899243-21-043033
Insider Transaction Report
Form 4
Transactions
- Purchase
Common Stock
2021-11-02$14.00/sh+693,525$9,709,350→ 2,969,352 total(indirect: See footnote) - Purchase
Common Stock
2021-11-02$14.00/sh+16,475$230,650→ 70,540 total(indirect: See footnote) - Conversion
Common Stock
2021-11-02+2,275,827→ 2,275,827 total(indirect: See footnote) - Conversion
Series D-1 Convertible Preferred Stock
2021-11-02−1,650,676→ 0 total(indirect: See footnote)→ Common Stock (1,650,676 underlying) - Conversion
Series E Convertible Preferred Stock
2021-11-02−5,975→ 0 total(indirect: See footnote)→ Common Stock (5,975 underlying) - Conversion
Common Stock
2021-11-02+54,065→ 54,065 total(indirect: See footnote) - Conversion
Series D-2 Convertible Preferred Stock
2021-11-02−8,876→ 0 total(indirect: See footnote)→ Common Stock (8,876 underlying) - Conversion
Series E Convertible Preferred Stock
2021-11-02−251,545→ 0 total(indirect: See footnote)→ Common Stock (251,545 underlying) - Conversion
Series D-2 Convertible Preferred Stock
2021-11-02−373,606→ 0 total(indirect: See footnote)→ Common Stock (373,606 underlying) - Conversion
Series D-1 Convertible Preferred Stock
2021-11-02−39,214→ 0 total(indirect: See footnote)→ Common Stock (39,214 underlying)
Medicxi Growth I LP
10% Owner
Transactions
- Conversion
Series D-2 Convertible Preferred Stock
2021-11-02−8,876→ 0 total(indirect: See footnote)→ Common Stock (8,876 underlying) - Purchase
Common Stock
2021-11-02$14.00/sh+693,525$9,709,350→ 2,969,352 total(indirect: See footnote) - Conversion
Series D-1 Convertible Preferred Stock
2021-11-02−39,214→ 0 total(indirect: See footnote)→ Common Stock (39,214 underlying) - Conversion
Series E Convertible Preferred Stock
2021-11-02−5,975→ 0 total(indirect: See footnote)→ Common Stock (5,975 underlying) - Conversion
Common Stock
2021-11-02+2,275,827→ 2,275,827 total(indirect: See footnote) - Conversion
Common Stock
2021-11-02+54,065→ 54,065 total(indirect: See footnote) - Conversion
Series D-2 Convertible Preferred Stock
2021-11-02−373,606→ 0 total(indirect: See footnote)→ Common Stock (373,606 underlying) - Conversion
Series D-1 Convertible Preferred Stock
2021-11-02−1,650,676→ 0 total(indirect: See footnote)→ Common Stock (1,650,676 underlying) - Conversion
Series E Convertible Preferred Stock
2021-11-02−251,545→ 0 total(indirect: See footnote)→ Common Stock (251,545 underlying) - Purchase
Common Stock
2021-11-02$14.00/sh+16,475$230,650→ 70,540 total(indirect: See footnote)
Medicxi Growth Co-Invest I LP
10% Owner
Transactions
- Purchase
Common Stock
2021-11-02$14.00/sh+16,475$230,650→ 70,540 total(indirect: See footnote) - Conversion
Series D-1 Convertible Preferred Stock
2021-11-02−1,650,676→ 0 total(indirect: See footnote)→ Common Stock (1,650,676 underlying) - Conversion
Series D-2 Convertible Preferred Stock
2021-11-02−373,606→ 0 total(indirect: See footnote)→ Common Stock (373,606 underlying) - Conversion
Series E Convertible Preferred Stock
2021-11-02−251,545→ 0 total(indirect: See footnote)→ Common Stock (251,545 underlying) - Conversion
Common Stock
2021-11-02+2,275,827→ 2,275,827 total(indirect: See footnote) - Conversion
Series E Convertible Preferred Stock
2021-11-02−5,975→ 0 total(indirect: See footnote)→ Common Stock (5,975 underlying) - Conversion
Common Stock
2021-11-02+54,065→ 54,065 total(indirect: See footnote) - Conversion
Series D-1 Convertible Preferred Stock
2021-11-02−39,214→ 0 total(indirect: See footnote)→ Common Stock (39,214 underlying) - Conversion
Series D-2 Convertible Preferred Stock
2021-11-02−8,876→ 0 total(indirect: See footnote)→ Common Stock (8,876 underlying) - Purchase
Common Stock
2021-11-02$14.00/sh+693,525$9,709,350→ 2,969,352 total(indirect: See footnote)
Medicxi Growth I GP Ltd
10% Owner
Transactions
- Purchase
Common Stock
2021-11-02$14.00/sh+693,525$9,709,350→ 2,969,352 total(indirect: See footnote) - Conversion
Common Stock
2021-11-02+2,275,827→ 2,275,827 total(indirect: See footnote) - Conversion
Common Stock
2021-11-02+54,065→ 54,065 total(indirect: See footnote) - Conversion
Series D-1 Convertible Preferred Stock
2021-11-02−1,650,676→ 0 total(indirect: See footnote)→ Common Stock (1,650,676 underlying) - Conversion
Series D-2 Convertible Preferred Stock
2021-11-02−8,876→ 0 total(indirect: See footnote)→ Common Stock (8,876 underlying) - Purchase
Common Stock
2021-11-02$14.00/sh+16,475$230,650→ 70,540 total(indirect: See footnote) - Conversion
Series D-2 Convertible Preferred Stock
2021-11-02−373,606→ 0 total(indirect: See footnote)→ Common Stock (373,606 underlying) - Conversion
Series E Convertible Preferred Stock
2021-11-02−251,545→ 0 total(indirect: See footnote)→ Common Stock (251,545 underlying) - Conversion
Series D-1 Convertible Preferred Stock
2021-11-02−39,214→ 0 total(indirect: See footnote)→ Common Stock (39,214 underlying) - Conversion
Series E Convertible Preferred Stock
2021-11-02−5,975→ 0 total(indirect: See footnote)→ Common Stock (5,975 underlying)
Footnotes (6)
- [F1]The number of shares of Common Stock contained in Column 4 of Table I, Rows 1 and 3, are the combined total of each share of Series D-1 Convertible Preferred Stock, Series D-2 Convertible Preferred Stock and Series E Convertible Preferred Stock which immediately prior to the closing of the Issuer's initial public offering ("IPO") converted into shares of the Issuer's Common Stock, on a 13.7-for one basis without payment or further consideration and had no expiration date.
- [F2]Held by Medicxi Growth I LP, a Jersey limited partnership ("Medicxi Growth I"). Medicxi Growth I GP Limited, a Jersey limited liability company ("MGI GP"), is the sole managing general partner of Medicxi Growth I, and Medicxi Ventures Management (Jersey) Limited, a Jersey limited liability company ("Medicxi Manager") is the sole manager of Medicxi Growth I. The Reporting Persons disclaim Section 16 beneficial ownership of the securities held by Medicxi Growth I, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that they have beneficial ownership of such shares for Section 16 or any other purpose.
- [F3]Held by Medicxi Growth Co-Invest I LP, a Jersey limited partnership ("Medicxi Growth Co-Invest I"). MGI GP is the sole managing general partner of Medicxi Growth Co-Invest I, and Medicxi Manager is the sole manager of Medicxi Growth Co-Invest I. The Reporting Persons disclaim Section 16 beneficial ownership of the securities held by Medicxi Growth Co-Invest I, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that they have beneficial ownership of such shares for Section 16 or any other purpose.
- [F4]Immediately prior to the closing of the IPO, the Series D-1 Convertible Preferred Stock automatically converted on a 13.7-for one basis into Common Stock without payment or further consideration. The Series D-1 Convertible Preferred Stock had no expiration date.
- [F5]Immediately prior to the closing of the IPO, the Series D-2 Convertible Preferred Stock automatically converted on a 13.7-for one basis into Common Stock without payment or further consideration. The Series D-2 Convertible Preferred Stock had no expiration date.
- [F6]Immediately prior to the closing of the IPO, the Series E Convertible Preferred Stock automatically converted on a 13.7-for one basis into Common Stock without payment or further consideration. The Series E Convertible Preferred Stock had no expiration date.
Documents
Issuer
Aura Biosciences, Inc.
CIK 0001501796
Entity typeother
Related Parties
1- filerCIK 0001715578
Filing Metadata
- Form type
- 4
- Filed
- Nov 3, 8:00 PM ET
- Accepted
- Nov 4, 5:00 PM ET
- Size
- 32.1 KB